Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

European urology oncology·2026
Same author

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Molecular cancer·2026
Same author

Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

Nature medicine·2026
Same author

Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials.

European urology oncology·2026
Same author

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

Journal for immunotherapy of cancer·2026
Same author

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Nov 6, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Emerging Targeted Therapy for Bladder Cancer.

Constance Thibault1, Yohann Loriot2

  • 1Medical Oncology Department, European Georges Pompidou Hospital, APHP.5, 20 rue Leblanc, Paris 75015, France.

Hematology/Oncology Clinics of North America
|May 7, 2021
PubMed
Summary
This summary is machine-generated.

Targeted therapies are revolutionizing urothelial carcinoma (UC) treatment. This review explores promising new drugs like FGFR inhibitors and antibody-drug conjugates for metastatic UC.

Keywords:
AntiangiogenicConjugated antibodiesFGFR inhibitorsPARP inhibitorsTargeted therapiesUrothelial carcinoma

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.7K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Related Experiment Videos

Last Updated: Nov 6, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.7K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.9K

Area of Science:

  • Oncology
  • Urothelial Carcinoma Biology
  • Molecular Pathways

Background:

  • Urothelial carcinoma (UC) has seen extensive research into its tumorigenesis over the past decade.
  • Historically, UC lacked approved targeted therapies.
  • Recent advancements have introduced novel therapeutic strategies.

Purpose of the Study:

  • To review the current landscape of targeted therapies for bladder urothelial carcinoma.
  • To highlight emerging molecular pathways and their therapeutic implications.

Main Methods:

  • Literature review of targeted therapies in bladder UC.
  • Analysis of clinical trial data for novel agents.
  • Synthesis of information on fibroblast growth factor receptor inhibitors, conjugated antibodies, PARP inhibitors, and antiangiogenics.

Main Results:

  • Several targeted therapies demonstrate significant promise in metastatic UC.
  • Fibroblast growth factor receptor (FGFR) inhibitors show efficacy.
  • Conjugated antibodies, PARP inhibitors, and antiangiogenics are also under evaluation.

Conclusions:

  • Targeted therapies represent a new frontier in managing advanced urothelial carcinoma.
  • Ongoing research is crucial for developing effective treatments for UC.
  • The reviewed agents offer hope for improved patient outcomes in metastatic settings.